AC
MIRM icon

Apogem Capital’s Mirum Pharmaceuticals MIRM Stock Holding History

Apogem Capital’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,032
Closed -$421K – 75
2022
Q3 		$421K Buy
20,032
+8,010
+67% +$193K 0.42% 80
2022
Q2 		$234K Buy
+12,022
New +$284K 0.21% 129

Other funds holding MIRM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Apogem Capital's MIRM Position: Q4 2022 in Review

Apogem Capital sold out of Mirum Pharmaceuticals (MIRM) in Q4 2022, closing a stake of 20,032 shares — an estimated $421K sold.

Apogem Capital first reported a position in MIRM in Q2 2022 and held it in 2 quarters. The position peaked at $421K in Q3 2022. 104 funds tracked by Wall St. Rank hold MIRM as of Q4 2022.

  • Apogem Capital reported no remaining Mirum Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Apogem Capital sold 20,032 Mirum Pharmaceuticals shares in Q4 2022, an estimated $421K.
  • Apogem Capital first reported a position in Mirum Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Apogem Capital's Mirum Pharmaceuticals position peaked at $421K in Q3 2022.
  • 104 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.